Connect with us

Eyecare

EternaTear Raises $4.9M in Funding

It’s developing a product for dry eye syndrome.

mm

Published

on

EternaTear, a startup company based in Raleigh, NC, has raised $4.9 million in funding, according to the North Carolina Biotechnology Center.

The company is working on a non-prescription product called EternaTear. It is an eyedrop intended to treat dry eye syndrome.

The Series A investment round was led by Carolina Angel Network and Keiretsu Forum, the North Carolina Biotechnology Center reports. Other investors included Band of Angels, Deep Work Capital, Duke Angel Network, Keiretsu Capital and various ophthalmologists, optometrists and others.

Tim Willis, CEO of EternaTear, was quoted saying that the funding “provides us the capital to develop our product for both the U.S. and European markets to help the 320 million globally who suffer from dry eye.”

The company’s immediate priorities include “completion of a multi-site clinical marketing study and U.S. Food and Drug Administration OTC registration,” according to the North Carolina Biotechnology Center.

Advertisement

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular